Clinical Report: Evaluation of Erxiekang Emplastra for Acute Gastroenteritis
Overview
This study assessed the efficacy and safety of Erxiekang Emplastra as an adjunctive treatment for pediatric acute gastroenteritis (AGE). Results indicated that its use was associated with shorter diarrhea duration and lower disease severity compared to standard therapy alone.
Background
Acute gastroenteritis (AGE) is a prevalent condition in children, leading to significant morbidity and mortality worldwide. Standard treatments often face challenges such as poor medication adherence and symptom control.
Data Highlights
Outcome
Exposed Group (Erxiekang)
Unexposed Group (Standard Therapy)
p-value
Diarrhea Duration (days)
3.83
4.92
< 0.01
3-day Modified Vesikari Scale (MVS)
2.90
4.51
< 0.01
Adverse Events
1.44% mild reactions
No severe events
N/A
Key Findings
Erxiekang Emplastra significantly reduced diarrhea duration (3.83 vs. 4.92 days, p < 0.01).
Lower 3-day Modified Vesikari Scale scores were observed in the exposed group (2.90 vs. 4.51, p < 0.01).
Adjunctive therapy was independently associated with reduced diarrhea duration (β = –0.38, p < 0.01).
Only 1.44% of patients experienced mild transient local reactions with no severe adverse events reported.
The study included 1,089 eligible patients, with 417 in the exposed group and 672 in the unexposed group.
Clinical Implications
Findings indicate that Erxiekang Emplastra was associated with reduced diarrhea duration and severity.
Conclusion
Erxiekang Emplastra demonstrates favorable tolerability and efficacy in reducing diarrhea duration and severity in pediatric patients with acute gastroenteritis.
